An avian model of SSc confirmed that as in the human disease, TGF-β1 has a profibrotic activity on chicken fibroblasts, but that of TGF-β3 and particularly TGF-β2 is antifibrotic and may be a candidate for SSc therapy [28, 29]. The gene discussed is TGFB2; the disease is systemic sclerosis.